HomeCompareTAIPY vs SPHD

TAIPY vs SPHD: Dividend Comparison 2026

TAIPY yields 14.29% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TAIPY wins by $10.6K in total portfolio value
10 years
TAIPY
TAIPY
● Live price
14.29%
Share price
$14.00
Annual div
$2.00
5Y div CAGR
-8.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.1K
Annual income
$1,041.05
Full TAIPY calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — TAIPY vs SPHD

📍 TAIPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTAIPYSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TAIPY + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TAIPY pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TAIPY
Annual income on $10K today (after 15% tax)
$1,214.29/yr
After 10yr DRIP, annual income (after tax)
$884.89/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, TAIPY beats the other by $402.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TAIPY + SPHD for your $10,000?

TAIPY: 50%SPHD: 50%
100% SPHD50/50100% TAIPY
Portfolio after 10yr
$31.8K
Annual income
$804.20/yr
Blended yield
2.53%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TAIPY buys
0
SPHD buys
0
No recent congressional trades found for TAIPY or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTAIPYSPHD
Forward yield14.29%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.8%0%
Portfolio after 10y$37.1K$26.5K
Annual income after 10y$1,041.05$567.37
Total dividends collected$12.4K$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: TAIPY vs SPHD ($10,000, DRIP)

YearTAIPY PortfolioTAIPY Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$12,003$1,302.86$11,130$430.50+$873.00TAIPY
2$14,176$1,332.88$12,357$447.82+$1.8KTAIPY
3$16,510$1,341.75$13,687$464.65+$2.8KTAIPY
4$18,998$1,331.92$15,126$480.98+$3.9KTAIPY
5$21,634$1,306.29$16,682$496.78+$5.0KTAIPY
6$24,416$1,267.90$18,362$512.03+$6.1KTAIPY
7$27,345$1,219.66$20,174$526.72+$7.2KTAIPY
8$30,423$1,164.26$22,127$540.84+$8.3KTAIPY
9$33,657$1,104.05$24,230$554.39+$9.4KTAIPY
10$37,054$1,041.05$26,493$567.37+$10.6KTAIPY

TAIPY vs SPHD: Complete Analysis 2026

TAIPYStock

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

Full TAIPY Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this TAIPY vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TAIPY vs SCHDTAIPY vs JEPITAIPY vs OTAIPY vs KOTAIPY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.